Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample

Advances in Therapy

Volumn 31, Issue 4, 2014, Pages 410-425

  Yeaw, Jason ^a   Watson, Crystal ^b   Fox, Kathleen M ^c   Schabert, Vernon F ^a   Goodman, Seth ^a   Gandra, Shravanthi R ^b  

^a IQVIA   (United States)

^b AMGEN INC   (United States)

^c Strategic Healthcare Solutions LLC   (United States)

Author keywords

Adalimumab; Ankylosing spondylitis; Dermatology; Etanercept; Infliximab; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Rheumatology; Tumor necrosis factor blocker

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; CERTOLIZUMAB PEGOL; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; USTEKINUMAB; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PHOTOTHERAPY; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SYSTEMIC THERAPY; TOPICAL TREATMENT; UNITED STATES; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; FACTUAL DATABASE; HEALTH INSURANCE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; PROCEDURES; SPONDYLITIS, ANKYLOSING; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; DRUG SUBSTITUTION; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; MALE; MANAGED CARE PROGRAMS; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; WITHHOLDING TREATMENT;

EID: 84900826898     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0110-3     Document Type: Article

References (25)

1. Bathon J. Anti-TNF therapy for the treatment of rheumatoid arthritis. Johns Hopkins Arthritis Center, Baltimore, MD. 2011. http://www. hopkinsarthritis.org/arthritis-info/rheumatoid-arthritis/. Date Accessed 22 Aug 2013.
2. Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15:264-75.
3. Enbrel® (etanercept) Prescribing Information, Immunex Corporation, Thousand Oaks, CA. 2013.
4. Humira® (adalimumab) Prescribing Information, Abbott Laboratories, Abbott Park, IL. 2013.
5. Remicade® (infliximab) Prescribing Information, Centocor, Inc., Malvern, PA. 2013.
6. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32.
7. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67:1229-34.
8. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174.
9. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560-8.
10. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234-40.
11. Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837-46.
12. Strangfeld A, Hierse F, Kekow J, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856-62.
13. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.
14. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.
15. Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94.
16. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-46.
17. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84.
18. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. National Institute for Health and Care Excellence, London. 2007. http://www.nice.org.uk/TA130. Accessed 23 Aug 2013.
19. Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36:2171-7.
20. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol. 2004;31:2356-9.
21. Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford). 2007;46:1191-9.
22. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13-20.
23. Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31:825-35.
24. Wong BJ, Cifaldi MA, Roy S, Skonieczny DC, Stavrakas S. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. J Manag Care Pharm. 2011;17:313-20.
25. Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm. 2013;19:621-30.